BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 10739975)

  • 1. [Thalidomide and thrombosis].
    Flageul B; Wallach D; Cavelier-Balloy B; Bachelez H; Carsuzaa F; Dubertret L
    Ann Dermatol Venereol; 2000 Feb; 127(2):171-4. PubMed ID: 10739975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens.
    Cuadrado MJ; Karim Y; Sanna G; Smith E; Khamashta MA; Hughes GR
    Am J Med; 2005 Mar; 118(3):246-50. PubMed ID: 15745722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Thalidomide therapy of cutaneous lupus erythematosus].
    Bohmeyer J; Achenbach A; Westenberger M; Stadler R
    Hautarzt; 2002 Nov; 53(11):744-8. PubMed ID: 12402138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Thalidomide therapy for discoid lupus erythematosus].
    Lyakhovisky A; Baum S; Shpiro D; Salomon M; Trau H
    Harefuah; 2006 Jul; 145(7):489-92, 551. PubMed ID: 16900736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose thalidomide is an effective second-line treatment in cutaneous lupus erythematosus.
    Thomson KF; Goodfield MJ
    J Dermatolog Treat; 2001 Sep; 12(3):145-7. PubMed ID: 12243705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Photoprotection by thalidomide in patients with chronic cutaneous and systemic lupus erythematosus: discordant effects on minimal erythema dose and sunburn cell formation.
    Cummins DL; Gaspari AA
    Br J Dermatol; 2004 Aug; 151(2):458-64. PubMed ID: 15327555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy.
    Ordi-Ros J; Cortés F; Cucurull E; Mauri M; Buján S; Vilardell M
    J Rheumatol; 2000 Jun; 27(6):1429-33. PubMed ID: 10852265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of discoid lupus erythematosus with sulfasalazine: 11 cases].
    Delaporte E; Catteau B; Sabbagh N; Gosselin P; Breuillard F; Doutre MS; Broly F; Piette F; Bergoend H
    Ann Dermatol Venereol; 1997; 124(2):151-6. PubMed ID: 9740825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative.
    Lampropoulos CE; Sangle S; Harrison P; Hughes GR; D'Cruz DP
    Rheumatology (Oxford); 2004 Nov; 43(11):1383-5. PubMed ID: 15266063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pimecrolimus 1% cream for cutaneous lupus erythematosus.
    Kreuter A; Gambichler T; Breuckmann F; Pawlak FM; Stücker M; Bader A; Altmeyer P; Freitag M
    J Am Acad Dermatol; 2004 Sep; 51(3):407-10. PubMed ID: 15337984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic cutaneous lupus erythematosus. Thalidomide treatment of 11 patients.
    Hasper MF
    Arch Dermatol; 1983 Oct; 119(10):812-5. PubMed ID: 6614949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Classification of dermatologic manifestations in lupus erythematosus].
    Francès C; Barete S; Ayoub N; Piette JC
    Ann Med Interne (Paris); 2003 Feb; 154(1):33-44. PubMed ID: 12746657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on therapy--thalidomide in the treatment of lupus.
    Karim MY; Ruiz-Irastorza G; Khamashta MA; Hughes GR
    Lupus; 2001; 10(3):188-92. PubMed ID: 11315350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arterial thrombosis with immunomodulatory derivatives in the treatment of multiple myeloma: a single-center case series and review of the literature.
    Martin MG; Vij R
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):320-3. PubMed ID: 19717384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thalidomide induces amenorrhea in patients with lupus disease.
    Ordi J; Cortes F; Martinez N; Mauri M; De Torres I; Vilardell M
    Arthritis Rheum; 1998 Dec; 41(12):2273-5. PubMed ID: 9870886
    [No Abstract]   [Full Text] [Related]  

  • 16. Innovative management of lupus erythematosus.
    Knott HM; Martínez JD
    Dermatol Clin; 2010 Jul; 28(3):489-99. PubMed ID: 20510759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome.
    Cortés-Hernández J; Torres-Salido M; Castro-Marrero J; Vilardell-Tarres M; Ordi-Ros J
    Br J Dermatol; 2012 Mar; 166(3):616-23. PubMed ID: 21999437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fixed lupus erythematosus (its treatment with thalidomide)].
    Barba Rubio J; Franco González F
    Med Cutan Ibero Lat Am; 1977; 5(4):279-85. PubMed ID: 364211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thalidomide: an experience in therapeutic outcome and adverse reactions.
    Sharma NL; Sharma VC; Mahajan VK; Shanker V; Ranjan N; Gupta M
    J Dermatolog Treat; 2007; 18(6):335-40. PubMed ID: 17852637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case series of 48 patients treated with thalidomide.
    Doherty SD; Hsu S
    J Drugs Dermatol; 2008 Aug; 7(8):769-73. PubMed ID: 18720694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.